News EnteroBiotix cues up larger trial of microbiome IBS therapy EnteroBiotix has reported phase 2a proof-of-concept data for its therapy for irritable bowel syndrome (IBS) based on gut microbiome species.
News Nestle bids to take control of Seres’ C diff drug Vowst Swiss food giant Nestlé has said it wants to take full ownership of Seres Therapeutics’ Vowst microbiome therapy for Clostridiodes difficile infections (CDI), upg
R&D Reuters Pharma USA 2024 – Moreno Perugini Innovation in pharma comes in many forms, but at the end of the day what the industry cares about is results.
R&D Why gut bacteria is the next frontier in medicine Scientists search far and wide for treatments and cures for the diseases that cause great amounts of human suffering, from cancer to Parkinson's.
R&D JP Morgan 2024 – Xavier Duportet There were plenty of gene therapy companies around at JP Morgan 2024, and more than a few companies focused on the microbiome.
News Vedanta scores $106.5m to take microbiome drug into ph3 In the face of a challenging biotech financing environment, Vedanta Bio has ra
R&D Ben Sidders on integrating causality in AI for R&D success Ben Sidders, chief scientific officer at Biorelate, discusses leveraging advanced data science methods to transform the focus and impact of R&D.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face